Physician profile
Corinne Trumble
NPI 1457839466
$3,282.74
in general payments reported to CMS, 2019-2025
33 companies · $794 in 2025
The $794 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $155 · 2022: $575 · 2023: $710 · 2024: $1,048 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $589.87 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $569.07 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $274.79 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $203.60 | 2021-2025 | |
| Astellas Pharma US INC | $183.02 | 2023-2025 | Veozah, Myrbetriq |
| Amgen INC. | $176.85 | 2021-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.95 | 2021-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $139.16 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $134.63 | 2024-2025 | Auvelity, Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $99.22 | 2022-2025 | |
| Exact Sciences Corporation | $83.58 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.28 | 2025 | Caplyta |
| Abbott Laboratories | $69.31 | 2024-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $67.43 | 2022-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $59.43 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.12 | 2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $42.02 | 2022 | |
| Novartis Pharmaceuticals Corporation | $36.21 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $35.20 | 2023-2024 | Nuedexta, Rexulti |
| Noven Therapeutics, LLC | $34.82 | 2024 | Xelstrym |
| Astrazeneca Pharmaceuticals LP | $27.03 | 2022-2024 | Farxiga |
| Optinose US, INC. | $21.11 | 2025 | |
| Idorsia Pharmaceuticals US INC | $20.02 | 2023 | Quviviq |
| Scpharmaceuticals INC. | $19.28 | 2025 | |
| Dynavax Technologies Corporation | $18.40 | 2024 | Heplisav-B |
| Daiichi Sankyo INC. | $17.60 | 2025 | Injectafer |
| Xeris Pharmaceuticals, INC. | $16.89 | 2024 | Gvoke Hypopen |
| Amarin Pharma, INC. | $16.77 | 2021 | |
| Gilead Sciences, INC. | $15.30 | 2021 | |
| Hikma Pharmaceuticals USA | $14.26 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.34 | 2021 | |
| Merck Sharp & Dohme LLC | $13.29 | 2024 | Vaxelis, Gardasil 9, Proquad |
| Teva Pharmaceuticals USA, INC. | $12.89 | 2023 | Airduo Digihaler |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corinne Trumble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.